Study shows AP-325 offers lasting pain relief without central side effects
Category: News
Positive opinion issued for marketing authorisation extension
Phase 3 trial of Descartes-08 in myasthenia gravis to start in 1H25
Patients and care partners may find once every four weeks maintenance dosing easier
Study highlights VE303’s potential in reducing recurrent CDI
Comparison shows improved survival rates for pancreatic cancer treatment
Orphan drug designation offers development incentives and potential market exclusivity
Phase 3 trial shows promising pain relief for acute pain patients
Europe’s first biomarker trial seeks to prevent Crohn’s Disease onset